Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children.
Anti-N-methyl-D-aspartate-receptor
Encephalitis
Herpes simplex virus
Rituximab
Journal
Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
14
10
2021
accepted:
24
01
2022
pubmed:
26
4
2022
medline:
21
9
2022
entrez:
25
4
2022
Statut:
ppublish
Résumé
The long-term response of two infants with anti-N-methyl-D-aspartate receptor (anti-NMDAR) post herpes simplex encephalitis treated with rituximab is reported here. Rituximab may improve the course of the disease and should be considered early as second-line treatment. Data on the long-term effect of rituximab in B cell depletion and immunoglobulins levels in infants are needed.
Identifiants
pubmed: 35467320
doi: 10.1007/s12098-022-04170-8
pii: 10.1007/s12098-022-04170-8
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1033Informations de copyright
© 2022. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Références
Steiner I, Kennedy PGE, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6:1015–28.
doi: 10.1016/S1474-4422(07)70267-3
Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72.
doi: 10.1016/S1474-4422(12)70310-1
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for longterm outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
doi: 10.1016/S1474-4422(18)30244-8
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899–904.
doi: 10.1093/cid/cir1038
Armangue T, Moris G, Cantarín-Extremera V, et al. Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85:1736–43.
doi: 10.1212/WNL.0000000000002125
Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72:902–11.
doi: 10.1002/ana.23689
Bartolini L. Practice Current: How do you treat anti-NMDA receptor encephalitis? Neurol Clin Pr. 2016;6:69–72.
doi: 10.1212/CPJ.0000000000000219
Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–50.
doi: 10.1212/WNL.0000000000000570
Deyà-Martínez A, Gordón Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020;7:e724.